AU2003294401C1 - Broad spectrum anti-viral therapeutics and prophylaxis - Google Patents

Broad spectrum anti-viral therapeutics and prophylaxis Download PDF

Info

Publication number
AU2003294401C1
AU2003294401C1 AU2003294401A AU2003294401A AU2003294401C1 AU 2003294401 C1 AU2003294401 C1 AU 2003294401C1 AU 2003294401 A AU2003294401 A AU 2003294401A AU 2003294401 A AU2003294401 A AU 2003294401A AU 2003294401 C1 AU2003294401 C1 AU 2003294401C1
Authority
AU
Australia
Prior art keywords
sialidase
composition
domain
seq
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2003294401A
Other languages
English (en)
Other versions
AU2003294401A1 (en
AU2003294401B2 (en
Inventor
Fang Fang
Michael Malakhov
Mang Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ansun Biopharma Inc
Original Assignee
Ansun Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ansun Biopharma Inc filed Critical Ansun Biopharma Inc
Publication of AU2003294401A1 publication Critical patent/AU2003294401A1/en
Application granted granted Critical
Publication of AU2003294401B2 publication Critical patent/AU2003294401B2/en
Priority to AU2008200954A priority Critical patent/AU2008200954B2/en
Publication of AU2003294401C1 publication Critical patent/AU2003294401C1/en
Assigned to NEXBIO INC. reassignment NEXBIO INC. Request for Assignment Assignors: FANG, FANG, YU, MANG
Assigned to ANSUN BIOPHARMA, INC. reassignment ANSUN BIOPHARMA, INC. Request to Amend Deed and Register Assignors: NEXBIO INC.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Nanotechnology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2003294401A 2002-11-22 2003-11-21 Broad spectrum anti-viral therapeutics and prophylaxis Expired AU2003294401C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008200954A AU2008200954B2 (en) 2002-11-22 2008-02-28 Broad spectrum anti-viral therapeutics and prophylaxis

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42853502P 2002-11-22 2002-11-22
US60/428,535 2002-11-22
US46421703P 2003-04-19 2003-04-19
US60/464,217 2003-04-19
PCT/US2003/037158 WO2004047735A2 (en) 2002-11-22 2003-11-21 Broad spectrum anti-viral therapeutics and prophylaxis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2008200954A Division AU2008200954B2 (en) 2002-11-22 2008-02-28 Broad spectrum anti-viral therapeutics and prophylaxis

Publications (3)

Publication Number Publication Date
AU2003294401A1 AU2003294401A1 (en) 2004-06-18
AU2003294401B2 AU2003294401B2 (en) 2007-11-29
AU2003294401C1 true AU2003294401C1 (en) 2008-09-18

Family

ID=32397132

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003294401A Expired AU2003294401C1 (en) 2002-11-22 2003-11-21 Broad spectrum anti-viral therapeutics and prophylaxis

Country Status (8)

Country Link
US (2) US8084036B2 (enExample)
EP (1) EP1567185B1 (enExample)
JP (1) JP5348651B2 (enExample)
KR (2) KR20050085130A (enExample)
CN (2) CN101804200A (enExample)
AU (1) AU2003294401C1 (enExample)
CA (1) CA2506526C (enExample)
WO (1) WO2004047735A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8084036B2 (en) * 2002-11-22 2011-12-27 Nexbio, Inc. Broad spectrum anti-viral therapeutics and prophylaxis
US7807174B2 (en) * 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
US8512710B2 (en) * 2002-11-22 2013-08-20 Ansun Biopharma, Inc. Class of therapeutic protein based molecules
WO2007070875A1 (en) * 2005-12-15 2007-06-21 Aerosol Science Laboratories, Inc. Treatment of active infections and related compositions
US20070190163A1 (en) 2006-01-24 2007-08-16 Malaknov Michael P Technology for preparation of macromolecular microspheres
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
CN101646775B (zh) 2006-12-28 2016-08-24 森托科尔奥索生物科技公司 用于产生脱唾液酸化免疫球蛋白的方法和载体
CA2989778C (en) * 2007-01-19 2020-06-30 Kai Pharmaceuticals, Inc. Method of modifying peptide compositions
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
EP3058954B1 (en) 2007-08-27 2017-03-01 Longhorn Vaccines and Diagnostics, LLC Immunogenic compositions and methods
ES2552858T3 (es) 2007-10-01 2015-12-02 Longhorn Vaccines And Diagnostics, Llc Recogida de muestras biológicas y sistema de transporte y métodos de uso
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
US8187591B2 (en) * 2007-10-11 2012-05-29 The Regents Of The University Of California Methods of treating coagulopathy
EP2356143A1 (en) * 2008-11-07 2011-08-17 Anhydro Biologicals Limited Vaccine compositions
JP2010229122A (ja) * 2009-03-06 2010-10-14 Kumamoto Univ 抗癌剤、医薬、及び癌疾患の検査薬
CN102448438A (zh) * 2009-03-26 2012-05-09 普马特里克斯公司 抗流行性感冒调配物及方法
JP2011037765A (ja) * 2009-08-11 2011-02-24 Kitasato Institute 新規ペプチド、並びにトリプシン阻害剤、抗インフルエンザウイルス剤、及び抗体
GB0916578D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
AU2011296343B2 (en) 2010-08-30 2015-12-10 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
US20130164338A1 (en) 2010-08-30 2013-06-27 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
CA3086367A1 (en) 2010-09-29 2012-04-05 Pulmatrix Operating Company, Inc. Monovalent metal cation dry powders for inhalation
PT2621488T (pt) 2010-09-29 2019-02-12 Pulmatrix Operating Co Inc Pós secos catiónicos
EP3494989B1 (en) 2012-01-26 2025-07-16 Longhorn Vaccines and Diagnostics, LLC Composite antigenic sequences and vaccines
JP2015508780A (ja) 2012-02-17 2015-03-23 アンサン バイオファーマ，インコーポレイテッド 免疫不全患者のインフルエンザ及びパラインフルエンザウイルスを処置するための方法、化合物、及び組成物
CN104487075A (zh) 2012-02-29 2015-04-01 普马特里克斯公司 可吸入干粉剂
EP2866792A4 (en) 2012-06-28 2016-08-17 Ansun Biopharma Inc MICROPARTICLE FORMULATIONS FOR DELIVERY TO LOWER AND CENTRAL RESPIRATORY PATHS AND METHOD OF PREPARING THEM
AU2014248455B2 (en) 2013-04-01 2018-12-06 Pulmatrix Operating Company, Inc. Tiotropium dry powders
WO2014201034A2 (en) 2013-06-10 2014-12-18 Ansun Biopharma, Inc. Treatment for polyomavirus infection
WO2015184356A1 (en) 2014-05-30 2015-12-03 Ansun Biopharma, Inc. Treatment of middle east respiratory syndrome coronavirus
WO2016044656A1 (en) * 2014-09-17 2016-03-24 Ansun Biopharma, Inc. Treatment of infection by human enterovirus d68
KR101629821B1 (ko) 2015-01-19 2016-06-21 주식회사 엔터플 Url 쿠폰을 이용한 디지털 상품 제공 방법 및 장치
WO2016115616A1 (en) * 2015-01-21 2016-07-28 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Inhibition of cellular proteases as treatment for influenza
CA2985652C (en) 2015-05-14 2020-03-10 Gerald W. FISHER Rapid methods for the extraction of nucleic acids from biological samples
US20180271997A1 (en) * 2016-05-31 2018-09-27 Tianxin Wang Methods and Reagents to Treat Tumor and Cancer
US11459398B2 (en) 2016-07-01 2022-10-04 The Board Of Trustees Of The Leland Stanford Junior University Conjugates for targeted cell surface editing
US20200085849A1 (en) * 2017-05-18 2020-03-19 Elysium Health, Inc. Methods and compositions for improving sleep
MX2020007024A (es) 2018-01-03 2020-10-28 Palleon Pharmaceuticals Inc Sialidasas humanas recombinantes, proteinas de fusion de sialidasa y metodos para usar las mismas.
GB201814905D0 (en) * 2018-09-13 2018-10-31 Herwald Heiko Treatment
CA3145772A1 (en) * 2019-07-03 2021-01-07 Palleon Pharmaceuticals Inc. Recombinant sialidases and methods of using the same
AU2020318955A1 (en) * 2019-07-23 2022-03-03 Longitude Therapeutics S.R.L. Platelet-facilitated delivery of therapeutic compounds
US12485166B2 (en) 2020-02-06 2025-12-02 Longhorn Vaccines And Diagnostics, Llc Vaccines for the treatment and prevention of zoonotic infections
GB2615470A (en) 2020-10-20 2023-08-09 Longhorn Vaccines & Diagnostics Llc Immunogenic antigens

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532215A (en) * 1992-09-30 1996-07-02 Lezdey; John Antiviral compositions and method of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3439089A (en) 1968-03-27 1969-04-15 Merck & Co Inc Medicated hard candy
US5643758A (en) 1987-03-10 1997-07-01 New England Biolabs, Inc. Production and purification of a protein fused to a binding protein
RU2054180C1 (ru) * 1991-08-21 1996-02-10 Жирнов Олег Петрович (н/п) Способ лечения вирусных респираторных инфекций
US5985859A (en) * 1994-04-14 1999-11-16 The University Of Alabama Methods of inhibiting bacterial sialidase
AU5546898A (en) * 1997-01-14 1998-08-07 Hopital Sainte-Justine Human lysosomal sialidase and therapeutic uses thereof
US6251392B1 (en) 1997-10-20 2001-06-26 Epicyte Pharmaceuticals, Inc. Epithelial cell targeting agent
ATE301715T1 (de) * 1998-10-16 2005-08-15 Fraunhofer Ges Forschung Durch molekulares pathogenicid vermittelte krankheitsresistenz in pflanzen
US6855801B1 (en) 1999-02-02 2005-02-15 Thomas Jefferson University Peptides modulating activities of heparin other glycosaminoglycans or proteoglycans
US6737511B1 (en) * 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
US20020025320A1 (en) * 1999-08-20 2002-02-28 Prosper Boyaka Sialidases as mucosal adjuvants
US8084036B2 (en) 2002-11-22 2011-12-27 Nexbio, Inc. Broad spectrum anti-viral therapeutics and prophylaxis
US7807174B2 (en) 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
US20070190163A1 (en) 2006-01-24 2007-08-16 Malaknov Michael P Technology for preparation of macromolecular microspheres

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532215A (en) * 1992-09-30 1996-07-02 Lezdey; John Antiviral compositions and method of use

Also Published As

Publication number Publication date
EP1567185B1 (en) 2020-02-19
CN1729013B (zh) 2012-10-03
CA2506526A1 (en) 2004-06-10
AU2003294401A1 (en) 2004-06-18
WO2004047735A3 (en) 2004-09-23
US20050004020A1 (en) 2005-01-06
CN1729013A (zh) 2006-02-01
EP1567185A4 (en) 2009-04-22
JP2006508193A (ja) 2006-03-09
EP1567185A2 (en) 2005-08-31
US8084036B2 (en) 2011-12-27
KR20090087971A (ko) 2009-08-18
WO2004047735A2 (en) 2004-06-10
HK1080763A1 (en) 2006-05-04
US20080075708A1 (en) 2008-03-27
JP5348651B2 (ja) 2013-11-20
CN101804200A (zh) 2010-08-18
CA2506526C (en) 2017-04-18
AU2003294401B2 (en) 2007-11-29
KR20050085130A (ko) 2005-08-29

Similar Documents

Publication Publication Date Title
AU2003294401C1 (en) Broad spectrum anti-viral therapeutics and prophylaxis
CA2823429C (en) Sialidase catalytic domain proteins
US10525109B2 (en) Class of therapeutic protein based molecules
AU2008200954B2 (en) Broad spectrum anti-viral therapeutics and prophylaxis
HK1080763B (en) Broad spectrum anti-viral compounds, pharmaceutical formulations and the use thereof
HK1246351B (en) A novel class of therapeutic protein based molecules
HK1246351A1 (en) A novel class of therapeutic protein based molecules
HK1224329B (en) A novel class of therapeutic protein based molecules

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 28 FEB 2008.

MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY THE ACCEPTANCE FEE HAS BEEN EXTENDED TO 29 MAY 2008.

FGA Letters patent sealed or granted (standard patent)
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 28 FEB 2008

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ FANG, FANG; YU, MANG AND MALAKHOV, MICHAEL

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PATENTEE(S) TO READ MANG YU; FANG FANG AND MICHAEL MALAKHOV . ADDRESS FOR SERVICE IN AUSTRALIA - PEGASUS IP PO BOX 160 TOOWONG QLD 4066

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ FANG, FANG; MALAKHOV, MICHAEL AND YU, MANG .

TH Corrigenda

Free format text: IN VOL 27 , NO 25 , PAGE(S) 3760 UNDER THE HEADING AMENDMENTS - AMENDMENTS MADE DELETE ALL REFERENCE TO 2003294401

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ FANG, FANG; YU, MANG AND MALAKHOV, MICHAEL

PC Assignment registered

Owner name: NEXBIO INC.

Free format text: FORMER OWNER WAS: FANG, FANG; YU, MANG

HB Alteration of name in register

Owner name: ANSUN BIOPHARMA, INC.

Free format text: FORMER NAME(S): NEXBIO INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired